ENDRA Life Sciences Inc. (NDRA)
Stock Price:
$0.780 USD
0.050 (6.85%)
Updated Oct 23, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
19.41M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-18.66M |
| Shares Out |
24.88M |
| EPS (ttm) |
-1.75 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 23, 2020 |
| Last Price |
$0.780 |
| Previous Close |
$0.730 |
| Change ($) |
0.050 |
| Change (%) |
6.85% |
| Day's Open |
0.738 |
| Day's Range |
0.703 - 0.789 |
| Day's Volume |
177,909 |
| 52-Week Range |
0.599 - 2.250 |
More Stats
| Market Cap |
19.41M |
| Enterprise Value |
19.37M |
| Earnings Date (est) |
Nov 11, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
24.88M |
| Float |
22.96M |
| EPS (basic) |
-2.15 |
| EPS (diluted) |
-1.75 |
| FCF / Share |
-0.75 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
577,777 |
| Short Ratio |
6.41 |
| Short % of Float |
2.52% |
| Beta |
1.60 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
18.59 |
| Revenue |
n/a |
| Operating Income |
-11.77M |
| Net Income |
-18.66M |
| Free Cash Flow |
-10.99M |
| Net Cash |
32,026 |
| Net Cash / Share |
0.00 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-242.91% |
| ROE |
-1,030.95% |
| ROIC |
-3,917.60% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (3)
| Buy |
3 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$5.08*
(551.28% upside)
Low
3.25
Current: $0.780
High
6.00
Target: 5.08
*Average 12-month price target from 3 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|
| Revenue | - | 0.01 | 0.35 | 0.52 | 1.41 |
| Revenue Growth | - | -98.24% | -31.8% | -63.44% | - |
| Gross Profit | - | 0.01 | 0.18 | 0.28 | 0.74 |
| Operating Income | -10.84 | -9.02 | -5.38 | -2.77 | -1.57 |
| Net Income | -17.53 | -9.80 | -5.38 | -2.78 | -2.28 |
| Shares Outstanding | 7.50 | 4.50 | 2.76 | 0.72 | 2.32 |
| Earnings Per Share | -2.34 | -2.17 | -1.95 | -3.84 | -0.98 |
| Operating Cash Flow | -8.59 | -7.70 | -3.30 | -1.32 | -0.84 |
| Capital Expenditures | -0.04 | -0.10 | -0.01 | - | -0.13 |
| Free Cash Flow | -8.63 | -7.80 | -3.31 | -1.32 | -0.98 |
| Cash & Equivalents | 6.17 | 6.47 | 5.60 | 0.14 | 0.02 |
| Total Debt | 0.71 | - | - | 0.95 | - |
| Net Cash / Debt | 5.47 | 6.47 | 5.60 | -0.81 | 0.02 |
| Assets | 7.18 | 7.22 | 6.12 | 0.49 | 0.49 |
| Liabilities | 2.42 | 0.97 | 0.85 | 1.38 | 0.24 |
| Book Value | 4.76 | 6.25 | 5.28 | -0.89 | 0.25 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
ENDRA Life Sciences Inc. |
| Country |
United States |
| Employees |
15 |
| CEO |
Francois Michelon |
Stock Information
| Ticker Symbol |
NDRA |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Diagnostics & Research |
| Unique Identifier |
NASDAQ: NDRA |
| IPO Date |
May 9, 2017 |
Description
ENDRA Life Sciences develops medical imaging technology based on the thermos-acoustic effect that improves the sensitivity and specificity of clinical ultrasound. It offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding. It also offers Nexus-128 system that combines light-based thermos-acoustics and ultrasound to address the imaging needs of researchers studying disease models in pre-clinical applications. ENDRA Life Sciences Inc. has collaborative research agreement with General Electric Company. The company was incorporated in 2007 and is based in Ann Arbor, Michigan.